Skip to main content

Month: March 2023

Rail Vision Announces Fourth Quarter and Full Year 2022 Financial Results

RA’ANANA, Israel, March 23, 2023 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), a development stage technology company seeking to revolutionize railway safety and the data-related market, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. “Capital from our Nasdaq IPO enabled us to strengthen our foundation during fiscal 2022, positioning us to pursue multiple exciting opportunities to accelerate new customer acquisitions in 2023 and beyond,” commented Shahar Hania, CEO of Rail Vision. “Our recent successes, including the Israeli Railways deal and US-based rail services customer agreement, demonstrate that our solutions are gaining traction among potential customers. We remain confident in our ability to create value for shareholders...

Continue reading

Aircraft Flight Control System Market is Estimated to Hit USD 20.84 Billion by 2028 at a CAGR of 6.03% from 2022 to 2028; Surge in Demand for Commercial Aircraft due to the Substantial Growth in Air Travel to Fuel Market Growth

SkyQuest’s latest report is a valuable resource that provides businesses with comprehensive insights into the key growth areas and innovations in the aircraft flight control system market. The report offers a crucial analysis of the market’s trends, opportunities, challenges, and competitive landscape, enabling businesses to make data-driven decisions that can enhance their operations. Moreover, the report provides a holistic view of the market, covering various segments and general aviation and highlighting the emerging trends and opportunities in each segment. This can help businesses tailor their strategies and offerings to meet the specific needs of different customer segments, thereby improving their competitiveness, profitability, and customer satisfaction. Westford USA, March 23, 2023 (GLOBE NEWSWIRE) — The aircraft...

Continue reading

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results

DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2022 and fiscal year 2022. Summary Highlights Revenue:Total revenues for fiscal year 2022 and Q4, 2022 were $74.8m and $18.0m respectively. Excluding our Covid focused PCR Viral Transport Media (“VTM”) products, full year 2022 revenues of $71.5m were 1.0% lower than in 2021 and Q4, 2022 revenues were 0.4% lower than in Q4, 2021. Our performance in 2022 was focused on our core flagship haemoglobins business, where our main diabetes product line experienced 27% overall revenue growth and over 60% higher instrument placements versus 2021. As highlighted by the 43% growth in...

Continue reading

CAPREIT Announces Timing of First Quarter 2023 Results & Conference Call

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today it will issue its financial results for the three months ended March 31, 2023 after markets close on: Friday, May 12, 2023 A conference call to discuss the results will be hosted by the CAPREIT senior management team on: Monday, May 15, 2023 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: (833) 950-0062International: +1 (929) 526-1599Access Code: 497373 The call will also be webcast live and accessible through the CAPREIT website at www.capreit.ca – click on “For Investors” and follow the link at the top of the page. A replay of the webcast will be available for 1 year after the webcast at the same link. The slide presentation to accompany management’s...

Continue reading

ERES REIT Announces Timing of First Quarter 2023 Results & Conference Call

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (“ERES”) (TSX:ERE.UN) announced today it will issue its financial results for the three months ended March 31, 2023 after markets close on: Wednesday, May 10, 2023 A conference call to discuss the results will be hosted by Phillip Burns, Chief Executive Officer and Jenny Chou, Chief Financial Officer on: Thursday, May 11, 2023 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: (833) 950-0062 International: + 1 (929) 526-1599 Access Code: 119808 The call will also be webcast live and accessible through the ERES website at www.eresreit.com – click on “Investor Info” and follow the link at the top of the page. A replay of the webcast will be available for 1 year after the webcast at the same link. The...

Continue reading

Pan American Energy Retains Clarus Securities for Capital Markets Services

CALGARY, Alberta, March 23, 2023 (GLOBE NEWSWIRE) — Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS6) is pleased to announce that it has retained the services of Clarus Securities Inc. (“Clarus”) to act as financial advisor to the Company. The Company has entered into a services agreement (the “Agreement“) with Clarus, pursuant to which Clarus has agreed to perform the following capital markets support services, including but not limited to; introducing the Company to capital market participants and/or institutional investors that may include investment funds, mutual funds, private capital sources or other potential strategic investors; introducing the Company to industry participants as well as strategic investors as potential joint-venture partners, as requested;...

Continue reading

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022. “Meaningful progress has been made this year as we streamlined our product candidate portfolio to focus on our most promising asset. We believe Landos is uniquely positioned to transform the treatment paradigm for patients with ulcerative colitis with our novel, oral, once-daily treatment NX-13,”...

Continue reading

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

– Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement – – Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance – – Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 – CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “Following...

Continue reading

iCoreConnect Inc. Delivers Strong Financial Results in 2022 With 60% Revenue Growth

OCOEE, FL, March 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – iCoreConnect, Inc., (OTCQB: ICCT), a leading cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, announces its full year 2022 results.  Highlights for the Years Ended December 2022 and 2021:  2022 2021 % GrowthRevenues $8.0MM $5.0MM 60%Subscribers 30K 25K 20%Gross Profit 72% 68%  iCoreConnect continued to deliver strong financial results with 2022 revenues growing 60% to $8MM versus $5MM in 2021. This growth was primarily driven by organic growth with a 20% increase in the number of subscribers year-over-year and additional uptake on product offerings for existing subscribers. The company continued to see growth in all its Software-as-a-Service...

Continue reading

Decisions taken at Cargotec’s Annual General Meeting 2023

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 23 MARCH 2023 AT 2:25 PM (EET) Decisions taken at Cargotec’s Annual General Meeting 2023 Cargotec Corporation’s Annual General Meeting was held today 23 March 2023 in Helsinki, Finland. The Annual General Meeting approved a distribution of a dividend of EUR 1.34 for each of class A shares and a dividend of EUR 1.35 for each outstanding class B shares. The dividend shall be paid to shareholders who on the record date of dividend distribution, 27 March 2023, are registered as shareholders in the company’s shareholder register. The dividend payment day is 4 April 2023. The meeting adopted the financial statements and consolidated financial statements, and approved the remuneration report. The meeting granted discharge from liability to the members of the Board of Directors and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.